Gast ::
| Hauptseite > Publikationsdatenbank > 18F-Labelled inhibitors for targeting of IDH1 mutant gliomas > print |
| Hauptseite > Publikationsdatenbank > 18F-Labelled inhibitors for targeting of IDH1 mutant gliomas > print |
| 001 | 1027684 | ||
| 005 | 20250203103451.0 | ||
| 037 | _ | _ | |a FZJ-2024-04002 |
| 041 | _ | _ | |a English |
| 100 | 1 | _ | |a Neumaier, Bernd |0 P:(DE-Juel1)166419 |b 0 |e Corresponding author |u fzj |
| 111 | 2 | _ | |a 25th International Symposium on Radiopharmaceutical Sciences |g ISRS2023 |c Honolulu, USA |d 2023-05-22 - 2023-05-26 |w USA |
| 245 | _ | _ | |a 18F-Labelled inhibitors for targeting of IDH1 mutant gliomas |
| 260 | _ | _ | |c 2023 |
| 336 | 7 | _ | |a Conference Paper |0 33 |2 EndNote |
| 336 | 7 | _ | |a Other |2 DataCite |
| 336 | 7 | _ | |a INPROCEEDINGS |2 BibTeX |
| 336 | 7 | _ | |a conferenceObject |2 DRIVER |
| 336 | 7 | _ | |a LECTURE_SPEECH |2 ORCID |
| 336 | 7 | _ | |a Conference Presentation |b conf |m conf |0 PUB:(DE-HGF)6 |s 1719202127_32506 |2 PUB:(DE-HGF) |x After Call |
| 500 | _ | _ | |a Supported by Helmholtz European Partnership (HEP) |
| 520 | _ | _ | |a Objectives: Low grade diffuse gliomas are primary brain tumorscharacterized by the presence of mutations in isocitrate dehydrogen-ase 1 (IDH1), which equip the enzyme with a neomorphic activity thatincreases production of 2-hydroxyglutarate [1]. High concentrations ofthis oncometabolite are thought to interfere with histone methylationand cellular differentiation, thereby promoting gliomagenesis. Inaddition, mutated IDH1 (mIDH1) has been recognized as a keybiomarker for differential diagnosis, since it is not present in themore aggressive glioblastomas. While current approaches for detec-tion of mIDH1 require invasive tissue sampling, positron emissiontomography (PET) with mIDH1-selective probes could allow for non-invasive assessment of the IDH status. Here, we describe thepreparation, radiofluorination and preliminary biological evaluationof two candidate PET tracers derived from the mIDH1-selectiveinhibitor Olutasidenib.Methods: The boronic acid pinacol ester precursor for coppermediated radiofluorination was prepared using para bromoaniline asthe starting material and Ellman’s sulfinamide as chiral auxiliary forthe formation of the desired S-enantiomer. However, due to significantproduction of the undesired R-enantiomer, we ultimately decided toprepare and radiolabel both R- and S-enantiomer in order to comparethem in cellular uptake assays. For radiofluorination, [ 18 F]fluoride wasloaded onto an anion exchange cartridge and eluted with TEAB inMeOH followed by removal of MeOH. An equimolar solution ofradiolabeling precursor and copper mediator in 1,3-dimethyl-2-imidazolidinone was then added and the mixture was stirred in airat 100 °C for 15 minutes, followed by deprotection with 0.3 M NaOH inH2 O at 80°C for 3 minutes. After HPLC-purification and formulation inphysiological saline solution, the radiotracers were subjected to apreliminary evaluation in wildtype and mIDH1-transfected U-87 MGglioma cell lines.Results: The protected (S) and (R) radiolabeling precursors wereproduced in 15 steps and the 18F-labeled R,S-enantiomers 2 and 3 werefurnished in radiochemical yields of 60 ± 11%, radiochemical purities of>99% and molar activities of 102–237 GBq/μmol. Tracers lipophilicity(logD7.4 ) was found to be 2.53 if measured in PBS buffer but negativewhen measured in water (logP). No degradation was observed duringincubation in rat blood plasma at 37°C over 60 minutes. In contrast ifthe tracer was spotted onto silica plates full degradation was observed.Cell uptake experiments revealed a significantly higher uptake intransfected rather than wild type cells for both [ 18F]1 and S-[18 F]2 butwhile 90% of the first could reach the cytoplasm, the latter mostlyremained in the medium, suggesting that it may only partially cross thecellular membrane.Conclusion: Three 18F-labelled mIDH1-selective inhibitors havebeen successfully prepared and shown to exhibit significantly higheruptake into mIDH1-expressing compared to wildtype glioma cells. Apreclinical evaluation will be performed on [ 18 F]1, while furtherexperiments will be conducted on [ 18 F]2 to explain the unexpectedresults and subsequently compare them with the results of [ 18F]3. |
| 536 | _ | _ | |a 5253 - Neuroimaging (POF4-525) |0 G:(DE-HGF)POF4-5253 |c POF4-525 |f POF IV |x 0 |
| 700 | 1 | _ | |a Cologni, Roberta |0 P:(DE-Juel1)184639 |b 1 |u fzj |
| 700 | 1 | _ | |a Holschbach, Marcus |0 P:(DE-Juel1)131824 |b 2 |u fzj |
| 700 | 1 | _ | |a Bier, Dirk |0 P:(DE-Juel1)131810 |b 3 |u fzj |
| 700 | 1 | _ | |a Carloni, Paolo |0 P:(DE-Juel1)145614 |b 4 |u fzj |
| 856 | 4 | _ | |u https://juser.fz-juelich.de/record/1027684/files/1-s2.0-S096980512300344X-main.pdf |y Restricted |
| 856 | 4 | _ | |u https://juser.fz-juelich.de/record/1027684/files/1-s2.0-S096980512300344X-main.gif?subformat=icon |x icon |y Restricted |
| 856 | 4 | _ | |u https://juser.fz-juelich.de/record/1027684/files/1-s2.0-S096980512300344X-main.jpg?subformat=icon-1440 |x icon-1440 |y Restricted |
| 856 | 4 | _ | |u https://juser.fz-juelich.de/record/1027684/files/1-s2.0-S096980512300344X-main.jpg?subformat=icon-180 |x icon-180 |y Restricted |
| 856 | 4 | _ | |u https://juser.fz-juelich.de/record/1027684/files/1-s2.0-S096980512300344X-main.jpg?subformat=icon-640 |x icon-640 |y Restricted |
| 909 | C | O | |o oai:juser.fz-juelich.de:1027684 |p VDB |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 0 |6 P:(DE-Juel1)166419 |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 1 |6 P:(DE-Juel1)184639 |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 2 |6 P:(DE-Juel1)131824 |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 3 |6 P:(DE-Juel1)131810 |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 4 |6 P:(DE-Juel1)145614 |
| 913 | 1 | _ | |a DE-HGF |b Key Technologies |l Natural, Artificial and Cognitive Information Processing |1 G:(DE-HGF)POF4-520 |0 G:(DE-HGF)POF4-525 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-500 |4 G:(DE-HGF)POF |v Decoding Brain Organization and Dysfunction |9 G:(DE-HGF)POF4-5253 |x 0 |
| 914 | 1 | _ | |y 2024 |
| 920 | _ | _ | |l yes |
| 920 | 1 | _ | |0 I:(DE-Juel1)INM-5-20090406 |k INM-5 |l Nuklearchemie |x 0 |
| 920 | 1 | _ | |0 I:(DE-Juel1)INM-9-20140121 |k INM-9 |l Computational Biomedicine |x 1 |
| 980 | _ | _ | |a conf |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-Juel1)INM-5-20090406 |
| 980 | _ | _ | |a I:(DE-Juel1)INM-9-20140121 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|